Physician profile
Michael Gannon
NPI 1225441215
$1,204.79
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $219 · 2021: $277 · 2023: $209 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $179.86 | 2019-2021 | |
| Novo Nordisk INC | $157.99 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $150.38 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $100.49 | 2020-2024 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $83.94 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $58.23 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $50.04 | 2019-2021 | |
| Abbvie INC. | $42.61 | 2023 | |
| Merck Sharp & Dohme LLC | $40.91 | 2019 | |
| Pfizer INC. | $36.16 | 2020-2021 | |
| Allergan, INC. | $36.15 | 2019-2020 | |
| Astellas Pharma US INC | $34.36 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $31.61 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $28.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.46 | 2020-2023 | Seglentis, Livalo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $21.03 | 2024 | Impella |
| Esperion Therapeutics, INC. | $18.39 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.27 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.40 | 2024 | Tradjenta, Jardiance |
| Sanofi-Aventis U.S. LLC | $14.13 | 2019 | |
| Sanofi Pasteur INC. | $12.86 | 2019 | |
| Eisai INC. | $11.64 | 2020 | |
| Ibsa Pharma INC. | $11.11 | 2019 | |
| Dynavax Technologies Corporation | $10.05 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.